2013 revised response criteria for myeloproliferative neoplasms8,9
| . | Essential thrombocythemia . | Polycythemia vera . | Myelofibrosis . |
|---|---|---|---|
| Complete response | X | X | X |
| Partial response | X | X | X |
| Clinical improvement | X | ||
| Stable disease | X | ||
| No response | X | X | |
| Relapse | X | ||
| Other responses* | Molecular | Molecular | Cytogenetic and molecular |
| . | Essential thrombocythemia . | Polycythemia vera . | Myelofibrosis . |
|---|---|---|---|
| Complete response | X | X | X |
| Partial response | X | X | X |
| Clinical improvement | X | ||
| Stable disease | X | ||
| No response | X | X | |
| Relapse | X | ||
| Other responses* | Molecular | Molecular | Cytogenetic and molecular |
See Table 1 in the article by Takahashi et al that begins on page 3784.
Complete response = eradication of a preexisting abnormality; partial response = >50% decrease in allele burden (with at least 20% mutant allele burden at baseline).
Other responses were measured in peripheral blood granulocytes.